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Usefulness of aberrant methylation of tissue factor pathway inhibitor 
2 (TFPI-2) in pure pancreatic juice in diagnosis for pancreatic 
carcinoma 
H. Watanabe, PH. Jiang, G. Okada, F. Yao, K. Ohtsubo and N. Sawabu. 
  Tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor and is 
thought to protect the matrix from degradation therefore counteracting tumor invasion and 
metastasis. Recently, aberrant methylation of TFPI-2 was detected frequently in pancreatic 
carcinoma (PCa) tissues and not in normal pancreatic tissues. We analyzed the aberrant 
methyaltion of TFPI-2 in the pure pancreatic juice (PPJ) from patients with various pancreatic 
diseases and evaluated its clinical usefulness in the diagnosis of PCa. 
   We evaluated the hypermethylation of TFPI-2 in PCa cell lines and PPJ aspirated 
endoscopically from patients with PCa, benign and malignant intraductal papillary mucinous 
neoplasm of the pancreas (IPMN), chronic pancreatitis (CP) by methylation-specific PCR (MSP) 
and real-time quantitative MSP (Q-MSP). 
  The incidence of the aberrant methylation of TFPI-2 using MSP was 7 (77.8%) of 9 PCa cell 
lines by Q-MSP and the expression of TFPI-2 mRNA by quantitative RT-PCR showed inverse 
correlation to the aberrant methylation of TFPI-2. Moreover, the incidence of the aberrant 
methylation of TFPI-2 in the PPJ was 21 (58.3%) of 36 PCa patients, 2 (20%) of 10 malignant 
IPMN and 1 (14.3%) of 7 benign IPMN and 1 (4.8%) of 21 CP by MSP assay. The incidence of 
the aberrant methylation of TFPI-2 in the PPJ with PCa was significantly higher than that with 
IPMN (p< 0.05) or CP (p< 0.001) as shown in Table. Using Q-MSP analysis, the ratio of 
hypermethylation TFPI-2/MyoD1 in the PPJ from patients with PCa, IPMN and CP was 6.62±
7.20, 0.58±1.02 and 1.28±1.73, respectively. The ratio of hypermethylationTFPI-2/MyoD1 in 
the PPJ with PCa was significantly higher than that with IPMN (p< 0.01) or CP (p< 0.05). Using 
the suitable cut-off value set as 2.5 according to the ROC curve, the incidence of the aberrant 
methylation of TFPI-2 in the PPJ by real-time MSP was 18 (62.1%) of 29 PCa patients, 1 (5.9%) 
of 17 IPMN and 3 (14.3%) of 21 CP, respectively. The incidence of quantitative TFPI-2 
hypermethylation in the PPJ with PCa was significantly higher than that with IPMN (p< 0.001) 
or CP (p< 0.001).  
   These results suggest that promoter methylation of TFPI-2 in the PPJ may be specific to PCa 
and a useful marker in the diagnosis of PCa. 
 
Table  The incidence of aberrant methylation of TFPI-2 in the pure pancreatic juice from   
       patients with various pancreatic diseases by methylation-specific PCR 
      Pancreatic disease      Incidence of aberrant methylation of TFPI-2 
       
      Pancreatic carcinoma          58.3% (21/36)     
      Malignant IPMN              20.0% (2/10)     *   *    ** 
      Benign   IPMN              14.2% (1/7) 
      Chronic pancreatitis            4.8% (1/21)   
      IPMN: intraductal papillary mucinous neoplasm, * : p< 0.05, ** : p< 0.001. 
  
